Clinical trials: Malignant Peritoneal Effusion
Malignant Pleural Effusion, Malignant Ascites
A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites
Malignant pleural effusion and/ or malignant ascites is generally defined by presence of malignant cells in the effusion fluid. The first-line therapies are mostly intrusive, medically demanding and inefficient, and therefore, it…
- Trial name
- NCT03736122
- Testing
- BSG-001
- Where
- Australia
- Volunteers
- 58 people
- Sponsor
- BioSyngen Pte Ltd
Malignant Pleural Effusion, Malignant Ascites
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE).
- Trial name
- RIOT2 (NCT06016179)
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Digestive System Cancer, Malignant Ascites
A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites
To evaluate the tolerance and safety of cinobufacini injection intraperitoneal treatment on digestive system cancer patients with malignant ascites, and propose dosage regimens for future clinical trials.
- Trial name
- NCT02530398
- Testing
- Cinobufacini Injection
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Dongfang Hospital Beijing University of Chinese Medicine
Malignant Ascites
Malignant Ascites Alfapump® Study
ProMAS is a prospective post-marketing, single-arm study to assess performance and safety of the Alfapump® system in the treatment of patients with malignant ascites.
- Trial name
- ProMAS (NCT04076566)
- Testing
- alfapump system
- Where
- United Kingdom
- Sponsor
- Sequana Medical N.V.
Malignant Pleural Effusion,, Malignant Ascites
Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion
Malignant ascites and pleural effusion are common symptoms in patients with advanced cancer. Currently, the management of malignant ascites and pleural effusion is a considerable clinical challenge.
- Trial name
- NCT01854866
- Testing
- Drug-packaging microparticles
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huazhong University of Science and Technology
Malignant Ascites Caused by Advanced Solid Tumors
A Clinical Study of GK02 in Malignant Ascites
A single-arm, single-center, open-label clinical study comprising three cohorts, evaluating the safety, preliminary efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) characteristics of autologous tumor-reactive T cells…
- Trial name
- NCT07378436
- Testing
- GK02
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Geekgene Technology Co., LTD
Cancer of Stomach, Adenocarcinoma, Ascites, Malignant
Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
This study is to evaluate the safety and efficacy of intraperitoneal injection of immune checkpoint inhibitor combined with zoledronic acid for the treatment of malignant ascites in gastric cancer.
- Trial name
- IPIZA (NCT06759064)
- Testing
- zoledronic acid plus Sintilimab intraperitoneal injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Qilu Hospital of Shandong University
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Advanced Solid Tumors, Malignant Pleural Effusions
WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)
This is a prospective, single-center, interventional, phase I, dose-escalation, single-arm study designed to evaluate the safety, tolerability, and preliminary efficacy of intrapleural/intraperitoneal infusion of WSK-IM02 in…
- Conditions
- Advanced Solid Tumors, Malignant Pleural Effusions, Malignant Ascites
- Trial name
- NCT07615894
- Testing
- WSK-IM02
- Where
- China
- Volunteers
- 9 people
- Sponsor
- WestVac Biopharma Co., Ltd.
Malignant Ascites
Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites
This study makes an observation over the objective response rate of autologous erythrocytes derived microparticles packaging methotrexate peritoneal perfusion and systemic therapy combination in the treatment of malignant…
- Trial name
- NCT03230708
- Testing
- Erythrocytes derived MPs containing MTX, convention drugs
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hui ting Xu，MD
Peritoneal Carcinoma Metastatic, Pleural Effusion, Malignant
Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors
CAR-T therapy has achieved unprecedented success in hematological tumors in recent years, but the progress of CAR-T cells in the treatment of solid tumors is facing difficulties.
- Conditions
- Peritoneal Carcinoma Metastatic, Pleural Effusion, Malignant, HER2 Positive Malignancies
- Trial name
- NCT04684459
- Testing
- Dual-targeting HER2 and PD-L1 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Sichuan University
Ovarian Neoplasms
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
The primary objective of this study was to compare the time between paracenteses before and after administration of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in ovarian cancer participants with symptomatic…
- Trial name
- NCT00396591
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- Where
- 3 sites in United States, Italy and 1 more
- Volunteers
- 16 people
- Sponsor
- Sanofi
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Neoplasms
CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers
This is a randomized phase IIIb study investigating the treatment of malignant ascites due to epithelial cancer (carcinomas) with the trifunctional antibody catumaxomab.
- Conditions
- Cancer, Neoplasms, Carcinoma, Malignant Ascites
- Trial name
- CASIMAS (NCT00822809)
- Testing
- Catumaxomab, Prednisolone
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 230 people
- Sponsor
- Neovii Biotech
Metastatic Gastric Adenocarcinoma
S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites
The purpose of this study is to compare the efficacy of S1 plus paclitaxel (intravenous injection \& intraperitoneal injection) plus bevacizumab (intraperitoneal injection) vs.
- Trial name
- NCT03990103
- Testing
- S1, Paclitaxel, Bevacizumab
- Where
- China
- Volunteers
- 66 people
- Sponsor
- China Medical University, China
Brenner Tumor, Malignant Ascites
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase II trial studies how well metformin hydrochloride and combination chemotherapy works in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02122185
- Testing
- metformin hydrochloride, Chemotherapy
- Where
- 10 sites in United States
- Volunteers
- 111 people
- Sponsor
- University of Chicago
Malignant Ascites
Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy
This study is a prospective, multi-cohort Phase Ib/II clinical trial, consisting of two stages as follows: 1. Phase Ib Dose-Escalation Stage To explore the dose-limiting toxicities (DLT) of intraperitoneally administered…
- Trial name
- NCT07397819
- Testing
- liposomal irinotecan monotherapy, Liposomal Irinotecan + rmhTNF-NC, Liposomal Irinotecan + Bevacizumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Dong sheng Zhang
Refractory Malignant Ascites
Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites
Malignant ascites often has a profound impact on the quality of life of cancer patients. Current treatments,including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end…
- Trial name
- NCT01852409
- Testing
- bevacizumab
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- Peking University
Peritoneal Neoplasms, Ascites
Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT
This trial studies efficacy and safety of combination of modulated electro-hyperthermia (mEHT) with Traditional Chinese Medicine (TCM) in treatment of peritoneal carcinomatosis with malignant ascites versus standard chemoinfusion…
- Conditions
- Peritoneal Neoplasms, Ascites, Yang Deficiency, Yin Deficiency
- Trial name
- OTMA-RII (NCT02638051)
- Testing
- Modulated Electro-Hyperthermia (mEHT), TCM Herbal Decoction (Shi Pi), IPCI (CDDP+5FU)
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Galenic Research Institute Ltd
Malignant Ascites
Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites
This study will evaluate the safety and efficacy of intraperitoneal administration of Bevacizumab to prevent the recurrence of malignant ascites.
- Trial name
- NCT02496286
- Testing
- Intraperitoneal Bevacizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Eastern Regional Medical Center